-
1
-
-
84908459097
-
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
-
Rampton D, Folkersen J, Fishbane S, et al.: Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99:1671–1676
-
(2014)
Haematologica
, vol.99
, pp. 1671-1676
-
-
Rampton, D.1
Folkersen, J.2
Fishbane, S.3
-
2
-
-
85041104035
-
The safety of available treatment options for iron-deficiency anemia
-
Muñoz M, Gómez-Ramírez S, Bhandari S: The safety of available treatment options for iron-deficiency anemia. Expert Opin Drug Saf 2018; 17:149–159
-
(2018)
Expert Opin Drug Saf
, vol.17
, pp. 149-159
-
-
Muñoz, M.1
Gómez-Ramírez, S.2
Bhandari, S.3
-
3
-
-
84899689238
-
-
EMEA/H/A-31/1322. European Medicines Agency,, [Last accessed July 15, 2018] Available from
-
European Medicines Agency: Assessment report for: Iron containing intravenous (IV) medicinal products. EMEA/H/A-31/1322. European Medicines Agency, 2013 [Last accessed: July 15, 2018] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500150771.pdf.
-
(2013)
Assessment report for: Iron containing intravenous (IV) medicinal products
-
-
-
4
-
-
77952118055
-
-
[Last accessed January 17, 2019] Available from
-
Ferinject (Ferric Carboxymaltose): Summary of Product Characteristics. [Last accessed: January 17, 2019] Available from: https://www.medicines.org.uk/emc/medicine/5910.
-
Summary of Product Characteristics
-
-
-
5
-
-
34547464547
-
-
[Last accessed January 17, 2019] Available from
-
Injectafer (Ferric Carboxymaltose Injection): Full Prescribing Information. [Last accessed: January 17, 2019] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203565s000lbl.pdf.
-
Full Prescribing Information
-
-
-
6
-
-
77952118055
-
-
[Last accessed January 17, 2019] Available from
-
Rienso (Ferumoxytol): Summary of Product Characteristics. [Last accessed: January 17, 2019] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002215/WC500129749.pdf.
-
Summary of Product Characteristics
-
-
-
7
-
-
84939265322
-
-
[Last accessed January 17, 2019] Available from
-
Feraheme (Ferumoxytol): Injection Full Prescribing Information. [Last accessed: January 17, 2019] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf.
-
Injection Full Prescribing Information
-
-
-
8
-
-
77952118055
-
-
[Last accessed January 17, 2019] Available from
-
Monofer (Iron [III] Isomaltoside 1000): Summary of Product Characteristics. [Last accessed: January 17, 2019] Available from: https://www.medicines.org.uk/emc/product/5676/smpc#PHARMACOLOGICAL_PROPS.
-
Summary of Product Characteristics
-
-
-
9
-
-
85063675534
-
-
Kirkland, QC, Pfizer Canada Inc.,, [Last accessed January 22, 2019] Available from
-
Monoferric (Iron Isomaltoside 1000 for Injection): Product Monograph. Kirkland, QC, Pfizer Canada Inc., 2018[Last accessed: January 22, 2019] Available from: https://www.pfizer.ca/sites/g/files/g10050796/f/201810/MONOFERRIC_PM_E_193890_22JUN2018.pdf.
-
(2018)
Product Monograph
-
-
-
10
-
-
84904512880
-
-
Mississauga, ON, Bellco Health Care Inc.,, [Last accessed January 17, 2019] Available from
-
Venofer (Iron Sucrose Injection): Product Monograph. Mississauga, ON, Bellco Health Care Inc., 2013[Last accessed: January 17, 2019] Available from: https://pdf.hres.ca/dpd_pm/00018889.PDF.
-
(2013)
Product Monograph
-
-
-
11
-
-
77952118055
-
-
[Last accessed January 17, 2019] Available from
-
Venofer (Iron Sucrose): Summary of Product Characteristics. [Last accessed: January 17, 2019] Available from: https://www.medicines.org.uk/emc/product/5911/smpc.
-
Summary of Product Characteristics
-
-
-
12
-
-
34547464547
-
-
[Last accessed January 17, 2019] Available from
-
Venofer (Iron Sucrose Injection): Full Prescribing Information. [Last accessed: January 17, 2019] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021135s017lbl.pdf.
-
Full Prescribing Information
-
-
-
13
-
-
85054726232
-
-
Mississauga, ON, Bellco Health Care Inc.,, [Last accessed January 17, 2019] Available from
-
DexIron (Iron Dextran Injection): Product Monograph. Mississauga, ON, Bellco Health Care Inc., 2017[Last accessed: January 17, 2019] Available from: https://pdf.hres.ca/dpd_pm/00037716.PDF.
-
(2017)
Product Monograph
-
-
-
14
-
-
77952118055
-
-
[Last accessed January 17, 2019] Available from
-
CosmoFer (Iron Dextran): Summary of Product Characteristics. [Last accessed: January 17, 2019] Available from: https://www.medicines.org.uk/emc/product/48/smpc#POSOLOGY.
-
Summary of Product Characteristics
-
-
-
15
-
-
34547464547
-
-
[Last accessed January 17, 2019] Available from
-
INFeD (Iron Dextran Injection): Full Prescribing Information. [Last accessed: January 17, 2019] Available from: https://www.allergan.com/assets/pdf/infed_pi.
-
Full Prescribing Information
-
-
-
16
-
-
85036517771
-
-
Laval, QC, sanofi-aventis Canada Inc.,, [Last accessed January 17, 2019] Available from
-
Ferrlecit (Sodium Ferric Gluconate Complex in Sucrose Injection): Product Monograph. Laval, QC, sanofi-aventis Canada Inc., 2016[Last accessed: January 17, 2019] Available from: https://pdf.hres.ca/dpd_pm/00037569.PDF.
-
(2016)
Product Monograph
-
-
-
17
-
-
34547464547
-
-
[Last accessed January 17, 2019] Available from
-
Ferrlecit (Sodium Ferric Gluconate Complex in Sucrose Injection): Full Prescribing Information. [Last accessed: January 17, 2019] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020955s013s015lbl.pdf.
-
Full Prescribing Information
-
-
-
18
-
-
79954432935
-
World Allergy Organization guidelines for the assessment and management of anaphylaxis
-
Simons FE, Ardusso LR, Bilò MB, et al.: World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011; 4:13–37
-
(2011)
World Allergy Organ J
, vol.4
, pp. 13-37
-
-
Simons, F.E.1
Ardusso, L.R.2
Bilò, M.B.3
-
19
-
-
84946037337
-
2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
-
Simons FE, Ebisawa M, Sanchez-Borges M, et al.: 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J 2015; 8:32
-
(2015)
World Allergy Organ J
, vol.8
, pp. 32
-
-
Simons, F.E.1
Ebisawa, M.2
Sanchez-Borges, M.3
-
21
-
-
77956430490
-
Glucocorticoids for the treatment of anaphylaxis: cochrane systematic review
-
Choo KJ, Simon E, Sheikh A: Glucocorticoids for the treatment of anaphylaxis: cochrane systematic review. Allergy 2010; 65:1205–1211
-
(2010)
Allergy
, vol.65
, pp. 1205-1211
-
-
Choo, K.J.1
Simon, E.2
Sheikh, A.3
-
22
-
-
84879159167
-
Epinephrine: the drug of choice for anaphylaxis-a statement of the World Allergy Organization
-
Kemp SF, Lockey RF, Simons FE, et al.: Epinephrine: the drug of choice for anaphylaxis-a statement of the World Allergy Organization. World Allergy Organ J 2008; 1(7 Suppl):S18–S26
-
(2008)
World Allergy Organ J
, vol.1
, Issue.7
, pp. S18-S26
-
-
Kemp, S.F.1
Lockey, R.F.2
Simons, F.E.3
-
23
-
-
85048001207
-
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
-
Zuberbier T, Aberer W, Asero R, et al.: The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73:1393–1414
-
(2018)
Allergy
, vol.73
, pp. 1393-1414
-
-
Zuberbier, T.1
Aberer, W.2
Asero, R.3
-
24
-
-
85028506249
-
Acute and chronic urticaria: evaluation and treatment
-
Schaefer P: Acute and chronic urticaria: evaluation and treatment. Am Fam Physician 2017; 95:717–724
-
(2017)
Am Fam Physician
, vol.95
, pp. 717-724
-
-
Schaefer, P.1
-
25
-
-
84899496074
-
The diagnosis and management of acute and chronic urticaria: 2014 update
-
Bernstein JA, Lang DM, Khan DA, et al.: The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133:1270–1277
-
(2014)
J Allergy Clin Immunol
, vol.133
, pp. 1270-1277
-
-
Bernstein, J.A.1
Lang, D.M.2
Khan, D.A.3
-
27
-
-
85043357925
-
Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from The European Anaphylaxis Registry
-
Worm M, Francuzik W, Renaudin JM, et al.: Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from The European Anaphylaxis Registry. Allergy 2018; 73:1322–1330
-
(2018)
Allergy
, vol.73
, pp. 1322-1330
-
-
Worm, M.1
Francuzik, W.2
Renaudin, J.M.3
-
28
-
-
84973130364
-
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) Controversies Conference
-
Macdougall IC, Bircher AJ, Eckardt KU, et al.: Iron management in chronic kidney disease: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2016; 89:28–39
-
(2016)
Kidney Int
, vol.89
, pp. 28-39
-
-
Macdougall, I.C.1
Bircher, A.J.2
Eckardt, K.U.3
-
29
-
-
84945930081
-
Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management
-
Szebeni J, Fishbane S, Hedenus M, et al.: Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol 2015; 172:5025–5036
-
(2015)
Br J Pharmacol
, vol.172
, pp. 5025-5036
-
-
Szebeni, J.1
Fishbane, S.2
Hedenus, M.3
-
31
-
-
84947431101
-
Comparative risk of anaphylactic reactions associated with intravenous iron products
-
Wang C, Graham DJ, Kane RC, et al.: Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015; 314:2062–2068
-
(2015)
JAMA
, vol.314
, pp. 2062-2068
-
-
Wang, C.1
Graham, D.J.2
Kane, R.C.3
-
32
-
-
0029795844
-
The safety of intravenous iron dextran in hemodialysis patients
-
Fishbane S, Ungureanu VD, Maesaka JK, et al.: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28:529–534
-
(1996)
Am J Kidney Dis
, vol.28
, pp. 529-534
-
-
Fishbane, S.1
Ungureanu, V.D.2
Maesaka, J.K.3
-
33
-
-
0028138372
-
Safe administration of iron dextran to a patient who reacted to the test dose
-
Monaghan MS, Glasco G, St John G, et al.: Safe administration of iron dextran to a patient who reacted to the test dose. South Med J 1994; 87:1010–1012
-
(1994)
South Med J
, vol.87
, pp. 1010-1012
-
-
Monaghan, M.S.1
Glasco, G.2
St John, G.3
-
34
-
-
34047200850
-
Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate
-
Sane R, Baribeault D, Rosenberg CL: Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate. Pharmacother 2007; 27:613–615
-
(2007)
Pharmacother
, vol.27
, pp. 613-615
-
-
Sane, R.1
Baribeault, D.2
Rosenberg, C.L.3
-
35
-
-
0034725897
-
Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation
-
Barton JC, Barton EH, Bertoli LF, et al.: Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000; 109:27–32
-
(2000)
Am J Med
, vol.109
, pp. 27-32
-
-
Barton, J.C.1
Barton, E.H.2
Bertoli, L.F.3
-
36
-
-
28544441741
-
Acute hypersensitivity reaction to ferric gluconate in a premedicated patient
-
Saadeh CE, Srkalovic G: Acute hypersensitivity reaction to ferric gluconate in a premedicated patient. Ann Pharmacother 2005; 39:2124–2127
-
(2005)
Ann Pharmacother
, vol.39
, pp. 2124-2127
-
-
Saadeh, C.E.1
Srkalovic, G.2
-
37
-
-
84904690812
-
Safety of intravenous iron formulations: facts and folklore
-
Auerbach M, Macdougall IC: Safety of intravenous iron formulations: facts and folklore. Blood Transfus 2014; 12:296–300
-
(2014)
Blood Transfus
, vol.12
, pp. 296-300
-
-
Auerbach, M.1
Macdougall, I.C.2
-
38
-
-
0035057037
-
Suspected iron dextran-related adverse drug events in hemodialysis patients
-
Fletes R, Lazarus JM, Gage J, et al.: Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37:743–749
-
(2001)
Am J Kidney Dis
, vol.37
, pp. 743-749
-
-
Fletes, R.1
Lazarus, J.M.2
Gage, J.3
-
40
-
-
0023760249
-
Successful prevention of an anaphylactoid reaction to iron dextran
-
Altman LC, Petersen PE: Successful prevention of an anaphylactoid reaction to iron dextran. Ann Intern Med 1988; 109:346–347
-
(1988)
Ann Intern Med
, vol.109
, pp. 346-347
-
-
Altman, L.C.1
Petersen, P.E.2
-
41
-
-
0034007116
-
Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran
-
Hickman MA, Bernstein IL, Palascak JE: Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran. Ann Allergy Asthma Immunol 2000; 84:262–263
-
(2000)
Ann Allergy Asthma Immunol
, vol.84
, pp. 262-263
-
-
Hickman, M.A.1
Bernstein, I.L.2
Palascak, J.E.3
-
42
-
-
0036630323
-
Lack of reaction to ferric gluconate in hemodialysis patients with a history of severe reaction to iron dextran
-
Bastani B, Rahman S, Gellens M: Lack of reaction to ferric gluconate in hemodialysis patients with a history of severe reaction to iron dextran. ASAIO J 2002; 48:404–406
-
(2002)
ASAIO J
, vol.48
, pp. 404-406
-
-
Bastani, B.1
Rahman, S.2
Gellens, M.3
-
43
-
-
85031093614
-
Two case reports of desensitization in patients with hypersensitivity to iron
-
Chapman E, Leal D, Alvarez L, et al.: Two case reports of desensitization in patients with hypersensitivity to iron. World Allergy Organ J 2017; 10:38
-
(2017)
World Allergy Organ J
, vol.10
, pp. 38
-
-
Chapman, E.1
Leal, D.2
Alvarez, L.3
-
44
-
-
84885419540
-
Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety
-
Bolton-Maggs PH, Cohen H: Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013; 163:303–314
-
(2013)
Br J Haematol
, vol.163
, pp. 303-314
-
-
Bolton-Maggs, P.H.1
Cohen, H.2
-
45
-
-
84909961726
-
-
[Last accessed August 29, 2018] Available from
-
Health Canada: Drug Product Database Online Query. [Last accessed: August 29, 2018] Available from: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp.
-
Drug Product Database Online Query
-
-
-
46
-
-
85030167806
-
Mechanisms, cofactors, and augmenting factors involved in anaphylaxis
-
Muñoz-Cano R, Pascal M, Araujo G, et al.: Mechanisms, cofactors, and augmenting factors involved in anaphylaxis. Front Immunol 2017; 8:1193
-
(2017)
Front Immunol
, vol.8
, pp. 1193
-
-
Muñoz-Cano, R.1
Pascal, M.2
Araujo, G.3
|